Archives: Speakers

Asiyah Nawab, MSc, is an Analyst at GlobalData’s London office with the Immunology team. She is involved in the production of in-depth forecasting reports, opportunity assessments, and competitive landscape analysis reports for immunology-related areas. Additionally, Asiyah has extensive research experience in the field of Pharmaceutics, with her research in the encapsulation of drugs within microparticles using emulsion electrospraying, supplemented through in vitro bacterial studies. Asiyah holds a Master of Science in Pharmaceutics from University College London (UCL), and a Bachelor’s degree in Biochemistry from King’s College London.

Chris has over 25 years of experience in the pharmaceutical industry. Over the past 10 years, he has focused on Market Access, Pricing, and Health Economics and Outcomes Research (HEOR), particularly in oncology. He is the Head of Market Access, Pricing, and HEOR for ex-US countries at Immunocore, a small biotech company based in Oxford (UK) and Rockville (USA). Chris is responsible for negotiating reimbursement and access across more than 30 countries.

Immunocore, which originated from Oxford University over 25 years ago, recently launched its first oncology medicine, tebentafusp, for the treatment of a rare cancer with no standard of care and a short life expectancy. The exceptional achievements of Immunocore and tebentafusp were recognised with the prestigious Prix Galien awards in both France and Germany. The launch is regarded as one of the most successful first launches for a biotech company.

Prior to joining Immunocore, Chris supported oncology efforts at AstraZeneca. Before moving into Market Access, he worked in research at GSK and SmithKline Beecham, and in pathology within the UK NHS. Chris holds a master’s degree in Economic Evaluation in Healthcare and a PhD in Biochemistry.

Beth Chamblin has 25 years of experience in Pharmaceutical/BioPharmaceutical development, including over 15 years in global clinical project management and 4 years in oncology project management. At IQVIA Biotech, she specializes in strategic oversight of late-phase global clinical programs, supporting emerging biotech companies. Beth has managed global Phase I-III studies across multiple regions and has expertise in novel trial designs. She also leads a team of 10 project managers/directors, providing mentoring and support. Her broad experience allows her to align each study with a company’s long-term goals, ensuring project success.

Eugenia Perozo is the editor for Investment Monitor, where she reports on political and economic trends affecting global FDI flows. She has covered the onslaught of US tariffs, travelling to an investment conference in Washington DC to report on how these have affected foreign business sentiment. She holds a Philosophy, Politics and Economics degree from Warwick University.

A competently skilled, flexible, dependable, hard-working, conscientious and ambitious clinical research professional with a solid employment history (including 10 years clinical trial management experience).
Hands-on responsibility for the leadership and conduct of clinical trials either through fully in-sourced, fully outsourced or hybrid operational model. Management and execution of Phase I-IV oncology and immuno-oncology clinical trials including the direction, planning, execution and interpretation of clinical trials under ICH/Good Clinical Practices.
Experience within Biotechs, Pharma, CRO and University Investigator led research studies in Phase I – IV trials.
Possess a thorough understanding of cross-functional clinical processes including data management, drug safety and regulatory affairs and have demonstrated the ability to lead a cross-functional team in a matrix environment.
Assists in the development and implementation of strategy, policies and procedures. Manage aspects of external vendor contracts including CRO.

Therapeutic areas worked in including Oncology, Infectious disease, Neurology, Vaccines, Cardiovascular, Diabetes and Dermatology.
Proficiency in Microsoft Office programs, a number of clinical trial management, safety database and document repository systems with the ability to pick up new skills and learn quickly.
Specialties: Clinical Trial Management, Data Management, study start up, ethics and regulatory submission, Trial Master File & Investigator site File maintenance.

• With over 30 years of experience in the contract research organization (CRO) industry, Ximena Valenzuela is a seasoned leader responsible for defining and executing account strategies in close partnership with Commercial teams. She excels in building and leading high-performing cross-functional teams, fostering a culture of accountability and operational excellence. Valenzuela is known for cultivating strong client relationships, ensuring delivery excellence across the portfolio, and driving strategic project execution. Her performance metrics include account revenue growth, new business generation, delivery timeliness and quality, financial forecasting accuracy, project margin optimization, and overall client satisfaction. The Therapeutic Area Expertise includes
  Oncology, Infectious Diseases, Cardiovascular, Neurology (Stroke), Gastroenterology, Rheumatology, Rare Diseases, Gene Therapy, and Ophthalmology. Valenzuela holds a Master of Science in Biochemistry and is based in Miami, Florida.